Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial
1. 系统已在2026-01-25 18:52:00对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1038/s41591-025-04049-z
文献链接: https://www.nature.com/articles/s41591-025-04049-z
其他信息:
出版社: Springer Science and Business Media LLC
作者: Grace Lai-Hung Wong; Man-Fung Yuen; Bingliang Lin; Mark W. Douglas; Peng Hu; Qing Xie; Fangfang Lv; Won Young Tak; Apinya Leerapun; Dong Joon Kim; Pisit Tangkijvanich; Young-Suk Lim; Chia-Yen Dai; James O’Beirne; Martin Weltman; Suparat Khemnark; Teerha Piratvisuth; Witsarut Manasirisuk; Xinyue Chen; Chun-Jen Liu; Jeong Heo; Jooho Lee; Junqi Niu; Rahul Kumar; Rajneesh Kumar; Chong Zhu; Ke Cao; Alex Tian; Xiaofei Chen; Qing Zhu; David Margolis; Jidong Jia; Zhi Hong
全文下载地址: https://www.nature.com/articles/s41591-025-04049-z.pdf
